Under Sigal’s leadership, more than 12 new medicines were brought to market. Among these was the first checkpoint inhibitor for cancer immunotherapy. His philanthropy is developing future leaders in the field. Helping Researchers Take Cancer Immunotherapy to the Next Level Family has been a major influence in Elliott Sigal’s life. His father, who worked at Eli Lilly, always encour- aged his son to pursue his inter- ests at the highest level, which is how Sigal came to earn a PhD in industrial engineering at Purdue University. “My mother’s strug- gle with cancer caused me to reflect on where my career would go next,” he said. He entered the Pritzker School of Medicine deter- mined to pursue interdisciplinary research that might someday be life-changing for other families. Sigal put his training to work in research and development in the phar- maceutical field, ultimately serving as executive vice president and chief scientific officer at Bristol-Myers Squibb from 2004 to 2013. Under his leadership, more than 12 new medicines were brought to market. Among these was the first checkpoint inhibitor for cancer immunotherapy. “Even though it’s profound when it works, immunotherapy works on fewer patients than we would like to see,” said Elliott Sigal, whose parents both died from cancer at young ages. “I dedicated my post-Bristol-Myers Squibb career to helping researchers take this to the next level.” To that end, the Sigals endowed UChicago’s first fellowship in cancer immunotherapy this year. The inaugural Elliott Sigal Fellow is Jonathan Trujillo, MD, PhD, whose research seeks to identify tumor-intrinsic oncogene pathways that mediate cancer immune evasion and resis- tance to immunotherapies. Trujillo is a member of the UChicago labo- ratory of Thomas Gajewski, MD, PhD, AbbVie Foundation Professor of Cancer Immunotherapy and Pathology, a pioneer in the field of cancer immunotherapy. The Sigals also established the Elliott Sigal Immuno- Oncology Lectureship. Elliott Sigal, MD, PhD, and Ruth Leff Sigal “The University of Chicago is at the forefront of cancer immunotherapy. … [They have] made major contributions to this area in the past and we should expect great things in the future.” — Elliott Sigal 23